Ra Pharmaceuticals, whose lead autoimmune disease drug candidate is viewed as a potential alternative to one of the most expensive medicines in the world, is being acquired by Belgian pharmaceuticals giant UCB in a $2.1 billion deal.
According to terms announced Thursday, UCB will pay $48 in cash for each Ra Pharma share. That’s a 111 percent premium over Ra’s Wednesday closing stock price. The deal allows Ra Pharma to place its experimental autoimmune disease drug in the hands of a company that has the resources to continue its late-stage development and if approved, sell it worldwide. Shares of Cambridge, MA-based… Read more »
UNDERWRITERS AND PARTNERS